KSCP:NASDAQKnightscope, Inc. Analysis
Data as of 2026-04-13 - not real-time
$3.36
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Knightscope’s shares are trading at $3.36, well below the 20‑day and 50‑day SMAs of roughly $4.02 and $3.90, indicating short‑term weakness. The RSI sits around 41, suggesting the stock is not yet oversold, while the MACD histogram is negative and the signal line is bearish, reinforcing a cautious near‑term outlook. Volatility is extreme at over 150% for the past 30 days and a beta above 2.5 points to heightened market sensitivity, which amplifies the overall risk profile.
Fundamentally, the company posts deep losses, negative margins and a trailing EPS of –$4, yet it holds $20.6 M in cash against $7.8 M of debt, providing a modest liquidity cushion. Recent news highlights a rapid workforce expansion to over 400 employees and a strategic push for triple‑digit revenue growth in 2026, while analyst consensus remains a strong‑buy with a median target of $12, implying a potential upside of more than 300%.
Fundamentally, the company posts deep losses, negative margins and a trailing EPS of –$4, yet it holds $20.6 M in cash against $7.8 M of debt, providing a modest liquidity cushion. Recent news highlights a rapid workforce expansion to over 400 employees and a strategic push for triple‑digit revenue growth in 2026, while analyst consensus remains a strong‑buy with a median target of $12, implying a potential upside of more than 300%.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Price below key moving averages
- Bearish MACD and neutral RSI
- High short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Negative earnings and margins
- Strong cash position relative to debt
- Analyst target median indicating substantial upside
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strategic workforce expansion and product rollout
- Management’s guidance toward triple‑digit growth
- Significant upside potential versus current price
Key Metrics & Analysis
Financial Health
Revenue Growth-9.80%
Profit Margin-298.32%
P/E Ratio-1.5
ROE-155.30%
ROA-60.98%
Debt/Equity28.02
P/B Ratio1.5
Op. Cash Flow$-30345000
Free Cash Flow$-22239376
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI41.3
Support$3.25
Resistance$5.96
MA 20$4.02
MA 50$3.90
MA 200$5.04
MACDBearish
VolumeDecreasing
Fear & Greed Index87.29
Valuation
Target Price$15.00
Upside/Downside346.43%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.53
Volatility151.60%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.